Discover how China is tackling its growing obesity crisis through innovative campaigns and cultural shifts. What does this mean for the future of health in the country?

With more than half of Chinese adults now classified as overweight, health authorities are stepping up measures to get people ...

Shares of weight-loss drugmakers Novo Nordisk A/S and Eli Lilly and Co. got a nice lift Monday, after a potential competitor decided to cancel development of its GLP-1 obesity drug. “We continue ...

That was music to the ears of investors in Novo Nordisk, which makes diabetes and obesity treatments Ozempic and Wegovy; and in Eli Lilly, which makes Mounjaro and Zepbound diabetes and obesity drugs.

Engaging her 12.7 million followers, the star praised the brand, adding that it's worked out better than its competitor Wegovy. Earlier this year she also revealed that similar drug Ozempic did ...

Fans were quick to comment on her shape with one follower named Wegovy_101 saying, 'U lost so much weight.' Model Evelyn Hernandez shared that Ashley is her role model: 'Such an inspiration for ...

Novo Nordisk’s breakneck sales growth has continued in the first quarter of this year with a 24% increase that was helped by a doubling in turnover of obesity blockbuster Wegovy. Group revenues ...

Within Novo Nordisk's comprehensive business update to investors, attention latched onto early data for an oral obesity therapy that outperformed the company’s big-selling GLP-1 agonist Wegovy ...